# Structure of the phosphocysteine intermediate of the phosphatase of regenerating liver PTP4A1

**Authors:** Luba Mahbub, Guennadi Kozlov, Caroline Knorn, Kalle Gehring

PMC · DOI: 10.1016/j.jbc.2025.110251 · The Journal of Biological Chemistry · 2025-05-19

## TL;DR

This study reveals how a specific phosphatase enzyme structure changes during a key reaction step, offering insights into its role in cancer and magnesium regulation.

## Contribution

The paper presents a novel crystal structure of a stabilized phosphocysteine intermediate in PRL1 and identifies unique catalytic properties of PRLs compared to other phosphatases.

## Key findings

- A C49S/D72A mutation stabilizes the phosphocysteine intermediate in PRL1 for weeks, enabling structural analysis.
- The phosphocysteine intermediate physically blocks binding to magnesium transport proteins (CNNMs).
- Aspartic acid mutations enhance catalytic rates in PRL paralogs but disrupt catalysis in other phosphatases.

## Abstract

Phosphatases of regenerating liver (PRL or PTP4A) are protein phosphatases implicated in cell growth, magnesium homeostasis, and cancer metastasis. During catalysis, a phosphocysteine intermediate forms, which must undergo hydrolysis to regenerate the active enzyme. In addition to dephosphorylating substrates, PRLs act as pseudo-phosphatases and bind CBS-pair domain divalent metal cation transport mediators (CNNMs) to regulate magnesium transport. In this study, we investigate the role of PRL residues in phosphocysteine hydrolysis using mutagenesis, enzyme assays, and X-ray crystallography. Loss of an aspartic acid and cysteine in the catalytic site disrupts hydrolysis and stabilizes the phosphocysteine intermediate for weeks. We use this C49S/D72A double mutant to determine the crystal structure of the cysteine-phosphorylated form of PRL1 (PTP4A1). The structure confirms that phosphocysteine sterically interferes with CNNM binding, consistent with previous biochemical studies. In vitro enzyme assays reveal the aspartic acid mutation increases the initial rate of catalysis for all three PRL paralogs while the homologous mutation in the phosphatases, PTP1B and PTPN12, disrupts catalysis. This highlights the mechanistic differences between PRLs and classical protein tyrosine phosphatases. Our findings refine our understanding of PRL catalysis and identify novel mutations for investigating PRL function in cancer and magnesium homeostasis.

## Linked entities

- **Genes:** PTP4A1 (protein tyrosine phosphatase 4A1) [NCBI Gene 7803], PTPN1 (protein tyrosine phosphatase non-receptor type 1) [NCBI Gene 5770], PTPN12 (protein tyrosine phosphatase non-receptor type 12) [NCBI Gene 5782]
- **Proteins:** PRL (prolactin), PTP4A2 (protein tyrosine phosphatase 4A2), PTPN1 (protein tyrosine phosphatase non-receptor type 1), PTPN12 (protein tyrosine phosphatase non-receptor type 12)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, PTP4A2 (protein tyrosine phosphatase 4A2) [NCBI Gene 8073] {aka HH13, HH7-2, HU-PP-1, OV-1, PRL-2, PRL2}, PTPN12 (protein tyrosine phosphatase non-receptor type 12) [NCBI Gene 5782] {aka PTP-PEST, PTPG1}, PTPN1 (protein tyrosine phosphatase non-receptor type 1) [NCBI Gene 5770] {aka PTP1B}, PTP4A1 (protein tyrosine phosphatase 4A1) [NCBI Gene 7803] {aka HH72, PRL-1, PRL1, PTP(CAAX1), PTPCAAX1}
- **Diseases:** cancer (MESH:D009369)
- **Chemicals:** magnesium (MESH:D008274), phosphocysteine (MESH:C057779), acid (MESH:D000143)
- **Mutations:** C49S, D72A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12192612/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12192612/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12192612/full.md

---
Source: https://tomesphere.com/paper/PMC12192612